Open Access<p><em>CYP2C19</em>*<em>2</em> Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese</p>
Author(s) -
Elaine Chow,
Emily Poon,
Benny S. P. Fok,
Juliana C.N. Chan,
Brian Tomlinson
Publication year - 2020
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s226200
Subject(s) - cyp2c19 , medicine , pharmacokinetics , gliclazide , pharmacogenetics , cyp2c9 , endocrinology , polymorphism (computer science) , pharmacology , genotype , metabolism , cytochrome p450 , biology , genetics , gene , insulin
Previous studies suggest gliclazide is metabolised primarily by CYP2C19 rather than CYP2C9, unlike other sulphonylureas. CYP2C19 *2 and *3 polymorphisms are more common in Asians.